{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:25:43Z","timestamp":1679232343036},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T00:00:00Z","timestamp":1505692800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s40259-017-0245-2","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T06:34:38Z","timestamp":1505716478000},"page":"465-468","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["GP2013: A Rituximab Biosimilar"],"prefix":"10.1007","volume":"31","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,18]]},"reference":[{"key":"245_CR1","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. \n                        http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/01\/WC500180219.pdf\n                        \n                    . Accessed 5 Sept 2017."},{"issue":"5","key":"245_CR2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40259-013-0036-3","volume":"27","author":"J Visser","year":"2013","unstructured":"Visser J, Feuerstein I, Stangler T, et al. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs. 2013;27(5):495\u2013507.","journal-title":"BioDrugs."},{"issue":"7","key":"245_CR3","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3109\/10428194.2013.843090","volume":"55","author":"A Silva Da","year":"2014","unstructured":"Da Silva A, Kronthaler U, Koppenburg V, et al. Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. Leuk Lymphoma. 2014;55(7):1609\u201317.","journal-title":"Leuk Lymphoma."},{"issue":"9","key":"245_CR4","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1136\/annrheumdis-2017-211281","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Cohen SB, Tony HP, et al. A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis. 2017;76(9):1598\u2013602.","journal-title":"Ann Rheum Dis."},{"key":"245_CR5","unstructured":"European Medicines Agency. Assessment report: Rixathon (international non-proprietary name: rituximab). 2017. \n                        http:\/\/www.ema.europa.eu\n                        \n                    . Accessed 5 Sept 2017."},{"issue":"8","key":"245_CR6","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1016\/S2352-3026(17)30106-0","volume":"4","author":"W Jurczak","year":"2017","unstructured":"Jurczak W, Moreira I, Kanakasetty GB, et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017;4(8):e350\u201361.","journal-title":"Lancet Haematol."},{"key":"245_CR7","unstructured":"European Medicines Agency. Summary of product characteristics: Rixathon 100 mg concentrate for solution for infusion, Rixathon 500 mg concentrate for solution for infusion. 2017. \n                        http:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170615137928\/anx_137928_en.pdf\n                        \n                    . Accessed 5 Sept 2017."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-017-0245-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0245-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-017-0245-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T06:11:38Z","timestamp":1506060698000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-017-0245-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,18]]},"references-count":7,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["245"],"URL":"https:\/\/doi.org\/10.1007\/s40259-017-0245-2","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,18]]}}}